FDA approves second GSK quadrivalent flu vax; Merck pulls Zilmax; Report: Eylea moves past Lucentis;

@FiercePharma: Trending online: Which are pharma's top 4 innovators? Hint: It's not the big guys. More | Follow @FiercePharma

@EricPFierce: FDA wants help figuring out how to stop addicts from getting to the APIs in opioid painkillers. Story from FiercePharmaManufacturing.com | Follow @EricPFierce

@CarlyHFierce: The latest in India vs. Big Pharma IP developments: Roche won't pursue Herceptin patents in India. Article | Follow @CarlyHFierce

> The U.K.'s BioIndustry Association (BIA) has lambasted the country's drug pricing plans, saying it could make the country a pharma innovation backwater. Story

> The FDA has approved FluLaval Quadrivalent, a second quadrivalent influenza vaccine from GlaxoSmithKline ($GSK). Release

> Merck ($MRK) said today it is temporarily halting sales of the animal supplement Zilmax, a week after Tyson Foods said it wouldn't buy cattle that had been fed the growth hormone. Announcement

> The FDA is now requiring that labels and guides on all fluoroquinolone antibacterial drugs be updated to better describe the serious and permanent nerve damage they can cause. Notice

> InnoPharma has launched acamprosate calcium in the U.S., the generic version of Forest Laboratories' ($FRX) Campral. Item 

> GlaxoSmithKline's Tyverb has been cleared in the EU for use in combination with Roche's ($RHHBY) Herceptin in patients with HER2-positive, hormone receptor-negative breast cancer. Story

> Canada has approved ThromboGenics' Jetrea for the treatment of symptomatic vitreomacular adhesion (VMA). Release

Medical Device News

@FierceMedDev: UPDATED: Bard ordered to pay $2M in vaginal mesh trial defeat. News | Follow @FierceMedDev

@DamianFierce: A global cybersecurity outfit is lending a hand to the medical device industry. Article | Follow @DamianFierce

@MarkHFierce: Heathrow Airport have been warned that female terrorists might strike with breast implant explosives. Report | Follow @MarkHFierce

@MichaelGFierce: ICYMI: St. Jude nets FDA approval for low-radiation ablation catheters. Article | Follow @MichaelGFierce

> China targets medical device misuse. Item

> Coloplast feels weight of rival's vaginal mesh legal woes. Story

> Gene By Gene joins Ambry to fight Myriad's Dx 'monopoly.' Report

Biotech News

@FierceBiotech: We're looking for the fiercest women in biotech for our 2013 report. Editor's note | Nomination form | Follow @FierceBiotech

@JohnCFierce: MannKind rewarded for positive Afrezza data with $40M financing. Report | Follow @JohnCFierce

@RyanMFierce: Scientists found a causal link between a tooth cavity bacterium and colon cancer in mice, potential drug target. More from TheScientist | Follow @RyanMFierce

@EmilyMFierce: SeattleBioMed wins $16M NIH grant for tuberculosis research. ICYMI yesterday from FierceBiotechResearch.com | Follow @EmilyMFierce

> Shkreli's biotech Retrophin zeroes in on $25M financing with 'major' pharma deal looming. Article

> Epizyme picks up FDA orphan nod for lead cancer drug as going public pays off. News

> Ophthotech eyes $85M IPO to fund PhIII for drug to prevent blindness. Report

And Finally... A report from BioTrends found that Eylea's patient share now stands at 26% of surveyed doctors' wet age-related macular degeneration patients, compared with 21% for Lucentis, suggesting that in two years Eylea has overtaken the first-to-market drug. Story

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.